BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 27256190)

  • 1. Is there any association between National Institute of Health category IV prostatitis and prostate-specific antigen levels in patients with low-risk localized prostate cancer?
    Doluoglu OG; Ceylan C; Kilinc F; Gazel E; Resorlu B; Odabas O
    Int Braz J Urol; 2016; 42(2):346-50. PubMed ID: 27256190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of NIH-IV prostatitis on free and free-to-total PSA.
    Stancik I; Lüftenegger W; Klimpfinger M; Müller MM; Hoeltl W
    Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values <10 ng/mL: Results of 564 Biopsy Naïve Cases.
    Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Panunzio A; De Michele M; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
    Urol Int; 2019; 103(4):415-422. PubMed ID: 31466070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen.
    Potts JM
    J Urol; 2000 Nov; 164(5):1550-3. PubMed ID: 11025702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer.
    Yuksel OH; Urkmez A; Akan S; Yldirim C; Verit A
    Asian Pac J Cancer Prev; 2015; 16(15):6407-12. PubMed ID: 26434851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen.
    Carver BS; Bozeman CB; Williams BJ; Venable DD
    J Urol; 2003 Feb; 169(2):589-91. PubMed ID: 12544313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy.
    Stimac G; Reljic A; Spajic B; Dimanovski J; Ruzic B; Ulamec M; Sonicki Z; Kraus O
    Scott Med J; 2009 Aug; 54(3):8-12. PubMed ID: 19725275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
    Dell'Atti L
    J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?
    Kim SJ; Jeong TY; Yoo DS; Park J; Cho S; Kang SH; Lee SH; Jeon SH; Lee TY; Park SY
    Yonsei Med J; 2015 Nov; 56(6):1492-6. PubMed ID: 26446628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
    Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
    Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy.
    Janbaziroudsari H; Mirzaei A; Maleki N
    Bull Cancer; 2016 Sep; 103(9):730-4. PubMed ID: 27345449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
    Magri V; Trinchieri A; Montanari E; Del Nero A; Mangiarotti B; Zirpoli P; de Eguileor M; Marras E; Ceriani I; Vral A; Perletti G
    Arch Ital Urol Androl; 2007 Jun; 79(2):84-92. PubMed ID: 17695414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of National Institutes of Health category IV prostatitis in accurately staging the newly diagnosed prostate cancer.
    Aglamis E; Tasdemir C; Ceylan C
    Ir J Med Sci; 2013 Sep; 182(3):463-7. PubMed ID: 23370973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk.
    Battikhi MN; Hussein I
    Int Urol Nephrol; 2006; 38(3-4):559-64. PubMed ID: 17318358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between literacy, compliance with prostate cancer screening, and cancer aggressiveness: results from a Brazilian screening study.
    Tobias-Machado M; Carvalhal GF; Freitas CH; Reis RB; Reis LO; Nogueira L; Machado RD; Magnabosco W; Vieira RA; Mauad EC; Carvalho AL; Faria EF;
    Int Braz J Urol; 2013; 39(3):328-34. PubMed ID: 23849582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.